不同病因肝硬化患者肠道菌群变化研究  

Study on the changes of gut microbiota in liver cirrhosis patients with different cause

作　　者：李玉珍 孙元培 廉晓晓 胡娜[2] 戚宇琪 郭晓霞[2] LI Yu-zhen;SUN Yuan-pei;LIAN Xiao-xiao;GUO Xiao-xia(Institute of Chinese Medicine in Shanxi Province(Taiyuan Shanxi,030012)China;不详)

机构地区：[1]山西省中医药研究院,山西太原030012 [2]山西省中医院

出　　处：《中西医结合肝病杂志》2022年第4期306-310,共5页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：北京中医药大学东直门医院中医内科学教育部重点实验室开放基金(No.2016-ZDSYSKFJJ-08);全国中医药创新骨干人才培训专项项目(No.2021CXGG-04)。

摘　　要：目的:研究不同病因肝硬化患者与健康对照组肠道微生态组成与功能差异,为肝硬化的诊疗提供新思路。方法:收集山西省中医院符合入排标准肝硬化患者及健康受试者粪便样本共76例,其中乙型肝炎患者45例,丙型肝炎患者6例,原发性胆汁性胆管炎患者8例,酒精性肝病患者7例以及健康对照组受试者10例。通过16S rRNA高通量测序进行菌群多样性、组成及功能分析。结果:共测出序列3 121 675条,代表序列98908条,平均长度为435.69 bp。健康对照组受试者菌群多样性及丰度均高于肝硬化各组,但各组间无明显差异(P>0.05)。从组成上看,与健康对照组相比,乙型肝炎组患者肠道放线菌门相对丰度降低,拟杆菌门相对丰度增高(P<0.05)。在属水平上共筛选出18种差异物种,其中柯林斯氏菌为健康对照组潜在生物标志物;毛螺菌属、杆菌属为乙型肝炎组潜在生物标志物;肠球菌、乳球菌为丙型肝炎组潜在生物标志物;致病杆菌属为酒精性肝病组潜在生物标志物。从功能上看,肝硬化组与疾病相关的通路有所上调。结论:与健康对照组相比,肝硬化组患者肠道菌群多样性及丰度有所下降,以丙型肝炎组和酒精性肝病组下降最为明显。各组优势物种及代谢通路存在明显差异。毛螺菌属、杆菌属具有抗乙型肝炎病毒的潜在作用。肠球菌、乳球菌在丙型肝炎的发生发展中起到一定作用。致病杆菌属通过遗传信息代谢通路影响酒精性肝病的发生。Objective:To study the differences in intestinal microecological composition and function between patients with different causes of liver cirrhosis and healthy controls, and to provide new thought for the diagnosis and treatment of liver cirrhosis.Methods:A total of 76 feces from patients with liver cirrhosis and healthy volunteer who were admitted to the Shanxi Provincial Hospital of Traditional Chinese Medicine were collected, including 45 cases of hepatitis B virus group(HBV), 6 cases of hepatitis C virus(HCV), 8 cases of primary biliary cirrhosis(PBC), 7 cases of alcoholic liver disease(ALD) and 10 cases of healthy control(HC). Diversity analysis, composition, and function analysis were performed by 16 S rRNA high-throughput sequencing. Results:A total of 3 121 675 sequences were detected, representing 98 908 sequences, with an average length of 435.69 bp. The flora diversity and abundance of HC were higher than those of cirrhosis groups, but there was no significant difference between the groups(P>0.05). From the perspective of composition, the relative abundance of Actinomycetes in HBV was decreased, and the relative abundance of Bacteroides was increased, which was statistically different from HC(P<0.05). A total of 18 different species were screened at the genus level, of which Collinsella was a potential biomarker in HC;Lachnospira and Lachnobacterium were potential biomarkers in HBV;intestine Enterococcus and Lactococcus are potential biomarkers in HCV;Xenorhabdus are potential biomarkers in ALD. From a functional point of metabolic pathway, the liver-cirrhosis group was upregulated with disease-related pathways. Conclusion:Compared with HC, the diversity and abundance of intestinal flora in the liver cirrhosis group decreased, and the decline was most obvious in HCV and ALD. The dominant species and metabolic pathways were significantly different in each group.Lachnospira and Lachnobacterium have potential effects against hepatitis B virus. Enterococcus and Lactococcus play a role in the occurrence of

关 键 词：肝硬化 16S rRNA 肠道菌群 代谢通路 

分 类 号：R256[医药卫生—中医内科学]